News for InnoCare Pharma Limited (9969.HK)

InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02

InnoCare Pharma , a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration has cleared the...

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

BEIJING — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases,…

As per the report by Fortune Business Insights, The Global Multiple Sclerosis Drugs Market size is projected to reach USD 31.90 Billion by 2030, at a CAGR...

Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech in a deal worth $170 million upfront and up to $1.5 billion in milestone payments.

InnoCare Pharma Limited press release (INCPF): FY Adj

InnoCare's drug sales soared after its key product was approved for Chinese medical insurance coverage, but hefty foreign exchange losses pushed the accounts into the red. Read more.

InnoCare Pharma Limited press release (INCPF): 9M loss for the first three quarters of 2022 was RMB444M.Revenue of RMB442M (+129% Y/Y).The cash and cash equivalents rose to RMB9.23B,...

Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The company is undervalued compared with its peers pending further progress in commercializing its products By Molly Wen